• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10x Genomics to Report Second Quarter 2025 Financial Results on August 7, 2025

    7/10/25 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TXG alert in real time by email

    PLEASANTON, Calif., July 10, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the second quarter ended June 30, 2025 after market close on Thursday, August 7, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

    10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.)

    Live audio of the webcast will be available on the "Investors" section of the company website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 45 days after the event.

    About 10x Genomics

    10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables, and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience, and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X (Twitter), Facebook, Bluesky or YouTube.

    Disclosure Information

    10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

    Contacts

    Investors: investors@10xgenomics.com

    Media: media@10xgenomics.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-to-report-second-quarter-2025-financial-results-on-august-7-2025-302502761.html

    SOURCE 10x Genomics, Inc.

    Get the next $TXG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TXG

    DatePrice TargetRatingAnalyst
    3/31/2026Mkt Perform → Outperform
    William Blair
    12/11/2025Buy → Neutral
    Citigroup
    12/2/2025$20.00Overweight → Equal-Weight
    Morgan Stanley
    9/11/2025$15.00Neutral
    Piper Sandler
    2/13/2025$25.00 → $12.00Outperform → Market Perform
    Leerink Partners
    9/3/2024$35.00Outperform
    Leerink Partners
    7/22/2024$24.00Hold → Buy
    Jefferies
    7/18/2024$40.00 → $20.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $TXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Suliman Shehnaaz sold $186,756 worth of shares (5,723 units at $32.63) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 31,722 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    6/18/26 4:08:03 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Teichmann Sarah A. was granted 8,829 shares, increasing direct ownership by 33% to 35,609 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    6/8/26 7:27:27 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Suliman Shehnaaz was granted 8,829 shares, increasing direct ownership by 31% to 37,445 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    6/8/26 7:26:38 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist

    Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a me

    6/19/26 3:00:00 AM ET
    $RAAQ
    $TXG
    $ILMN
    Blank Checks
    Finance
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer

    Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platformsPLEASANTON, Calif., June 17, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance research in novel diagnostics for bladder cancer. This collaboration is part of 10x's broader efforts to partner with lead

    6/17/26 9:00:00 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group

    Acquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the acquisition of Proteintech Genomics, a division within Proteintech Group, a company specializing in developing high-plex proteomic solutions for single cell and spatial applications on 10x platforms. The acquisition marks a strategic expansion of 10x's proteomics capabilities. Proteintech Genomics brings differentiated technologies, including its Human Discovery Panel, the l

    6/9/26 9:00:00 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    SEC Filings

    View All

    SEC Form 144 filed by 10x Genomics Inc.

    144 - 10x Genomics, Inc. (0001770787) (Subject)

    6/16/26 7:58:51 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - 10x Genomics, Inc. (0001770787) (Filer)

    6/8/26 4:46:52 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - 10x Genomics, Inc. (0001770787) (Filer)

    5/7/26 4:03:31 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    10x Genomics upgraded by William Blair

    William Blair upgraded 10x Genomics from Mkt Perform to Outperform

    3/31/26 8:05:20 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics downgraded by Citigroup

    Citigroup downgraded 10x Genomics from Buy to Neutral

    12/11/25 8:24:15 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded 10x Genomics from Overweight to Equal-Weight and set a new price target of $20.00

    12/2/25 8:22:39 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mateo Alan bought $445,572 worth of shares (40,000 units at $11.14), increasing direct ownership by 184% to 61,691 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    2/25/25 5:22:04 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by 10x Genomics Inc.

    SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

    11/8/24 2:46:37 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by 10x Genomics Inc.

    SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

    11/5/24 6:07:26 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by 10x Genomics Inc.

    SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

    10/4/24 2:14:32 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Financials

    Live finance-specific insights

    View All

    10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group

    Acquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the acquisition of Proteintech Genomics, a division within Proteintech Group, a company specializing in developing high-plex proteomic solutions for single cell and spatial applications on 10x platforms. The acquisition marks a strategic expansion of 10x's proteomics capabilities. Proteintech Genomics brings differentiated technologies, including its Human Discovery Panel, the l

    6/9/26 9:00:00 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics Reports First Quarter 2026 Financial Results

    PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026. Recent Updates Revenue was $150.8 million for the first quarter of 2026, representing a 3% decrease over the corresponding period of 2025. Excluding $16.8 million related to one-time license and royalty revenue in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025.Launched Atera, a new platform to redefine how biology is measured and understood.

    5/7/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026

    PLEASANTON, Calif., April 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2026 after market close on Thursday, May 7, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's

    4/15/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Leadership Updates

    Live Leadership Updates

    View All

    IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist

    Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a me

    6/19/26 3:00:00 AM ET
    $RAAQ
    $TXG
    $ILMN
    Blank Checks
    Finance
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics Announces Senior Leadership Changes

    PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer

    8/8/24 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Fanatics Announces Appointment of Lydia Jett and Jonathan Mildenhall to Board of Directors

    Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an

    5/5/22 8:30:00 AM ET
    $CPNG
    $GH
    $OZON
    Catalog/Specialty Distribution
    Consumer Discretionary
    Medical Specialities
    Health Care